Mr. Sarney has an MBA from Boston University and has spent more than 15 years working with biotechnology companies.
Avaxia Biologics is a biopharmaceutical company developing therapies for gastroenterological and inflammatory bowel disease applications.
More Articles on Gastroenterology:
NPS Pharmaceuticals’ Short Bowel Syndrome Treatment Shows Promise
RedHill Biopharma Seeks Patients for Phase III Crohn’s Disease Treatment Drug Trial
Kanawha Valley Gastroenterology Associates Selects Benchmark Systems EHR
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
